Monte Rosa Therapeutics has unveiled promising preclinical data on its CCNE1-directed molecular glue degrader (MGD), MRT-55811, which shows significant anti-tumor activity in CCNE1-amplified models of ovarian, breast, and gastric cancers. This first-in-class MGD demonstrates superior selectivity and reduced off-target effects compared to traditional CDK2 inhibitors, positioning it as a potential breakthrough in targeting a frequently amplified oncogene associated with various solid tumors.

The significance of MRT-55811 lies in its ability to induce deep degradation of cyclin E1 (CCNE1) and suppress downstream signaling pathways critical for tumor growth. In vivo studies indicated that MRT-55811 not only inhibited cellular proliferation in CCNE1-amplified cancer cell lines but also led to tumor regression and pathway suppression without affecting non-amplified cell lines. This targeted approach minimizes the dose-limiting toxicities often seen with less selective agents, which is a crucial advancement in cancer therapeutics.

The implications for the field are substantial, as this research could shift the paradigm in how we approach drug development for cancers driven by undruggable targets like CCNE1. The anticipated IND submission later this year could accelerate clinical trials and open new avenues for treating patients with high unmet medical needs in oncology. The success of MRT-55811 could also validate Monte Rosa’s QuEEN™ discovery engine, reinforcing the potential of molecular glue degraders as a viable therapeutic strategy in cancer treatment.

Source: globenewswire.com